View Older Stories View More Recent Stories
-
Viridian Therapeutic (VRDN) PT Raised to $45 at Evercore ISI
-
UBS Starts Viridian Therapeutic (VRDN) at Buy
-
TD Cowen on Viridian Therapeutic (VRDN): 'VRDN is a Top Pick'
-
Jefferies on Viridian Therapeutic (VRDN): 'Attractive 2026 Setup With Pot'l Launch and Pivotal Data', 'one of our Top Picks in 2026'
-
Viridian gets FDA priority review for thyroid eye disease drug
-
Truist Sees 'Catalyst-Rich 2026 Set-Up' for Viridian Therapeutic (VRDN)
-
FDA accepts Viridian Therapeutics' drug application with priority review
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
Goldman on Viridian (VRDN): 'believes the market can potentially grow ~2-3x at peak due to veli's and '003's potential to expand use in chronic TED'
-
Viridian Therapeutic (VRDN) PT Raised to $47 at Wedbush, Adds to BIL
-
William Blair Starts Viridian Therapeutic (VRDN) at Outperform
-
Truist Securities Starts Viridian Therapeutic (VRDN) at Buy
-
Viridian Therapeutic (VRDN) PT Raised to $45 at RBC Capital
-
Viridian Therapeutic (VRDN) PT Raised to $48 at Stifel
-
Viridian submits drug application to FDA for thyroid eye disease treatment
-
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
Viridian completes enrollment in phase 3 thyroid eye disease trials
-
Viridian Therapeutics (VRDN) files mixed shelf
-
Jefferies Assumes Viridian Therapeutic (VRDN) at Buy
-
Viridian Therapeutics, Inc. (VRDN) Reports In-Line Q2 EPS
-
B.Riley Reiterates Neutral Rating on Viridian Therapeutic (VRDN)
-
Viridian Therapeutics (VRDN) Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
-
Viridian Therapeutics (VRDN) Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease
-
Stifel on Viridian Therapeutic (VRDN): 'Rapidly Transitioning to Commercial Stage Company'
-
Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 11c
-
Viridian Therapeutics (VRDN) Appoints Jeff Ajer to its Board
-
Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
Viridian Therapeutics, Inc. (VRDN) Tops Q4 EPS by 22c
-
Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
RBC on Viridian (VRDN): 'Compelling THRIVE-2 Data Could Change the Game for Chronic TED & VRDN'; PT Raised
-
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
Oppenheimer Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
-
Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
-
TD Cowen Starts Viridian Therapeutic (VRDN) at Buy
-
Viridian Therapeutic (VRDN) PT Raised to $34 at H.C. Wainwright
-
Viridian Therapeutic (VRDN) PT Raised to $41 at Stifel
-
Viridian Therapeutics, Inc. (VRDN) Misses Q3 EPS by 9c
-
Needham Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
Viridian Therapeutic (VRDN) PT Raised to $44 at RBC Capital
-
Viridian Therapeutics (VRDN) Prices Upsized 10.67M Share Offering at $18.75/sh
-
Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs
-
Viridian Therapeutic (VRDN) PT Raised to $38 at Needham
-
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
-
Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley
-
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics
-
Viridian Therapeutics (VRDN) Announces Proposed $150M Share and Warrant Offering
-
Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel
-
Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
